Toronto Dominion Bank Makes New Investment in Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Toronto Dominion Bank acquired a new stake in Global Blood Therapeutics, Inc. (NASDAQ:GBTGet Rating) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 103,010 shares of the company’s stock, valued at approximately $3,015,000. Toronto Dominion Bank owned 0.16% of Global Blood Therapeutics at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in GBT. Huntington National Bank grew its holdings in shares of Global Blood Therapeutics by 90,600.0% in the fourth quarter. Huntington National Bank now owns 907 shares of the company’s stock valued at $27,000 after acquiring an additional 906 shares in the last quarter. US Bancorp DE lifted its position in shares of Global Blood Therapeutics by 52.7% during the third quarter. US Bancorp DE now owns 1,385 shares of the company’s stock worth $36,000 after acquiring an additional 478 shares in the last quarter. Advisor Group Holdings Inc. lifted its position in shares of Global Blood Therapeutics by 31.8% during the fourth quarter. Advisor Group Holdings Inc. now owns 1,865 shares of the company’s stock worth $55,000 after acquiring an additional 450 shares in the last quarter. Koshinski Asset Management Inc. raised its position in shares of Global Blood Therapeutics by 100.0% in the fourth quarter. Koshinski Asset Management Inc. now owns 2,000 shares of the company’s stock worth $59,000 after buying an additional 1,000 shares in the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Global Blood Therapeutics by 133.3% in the third quarter. Macquarie Group Ltd. now owns 3,411 shares of the company’s stock worth $87,000 after buying an additional 1,949 shares in the last quarter. 93.08% of the stock is currently owned by institutional investors.

Shares of GBT opened at $34.61 on Friday. The company has a market capitalization of $2.24 billion, a P/E ratio of -7.18 and a beta of 1.08. The company has a quick ratio of 8.45, a current ratio of 9.11 and a debt-to-equity ratio of 2.96. The firm has a 50 day moving average of $32.49 and a 200 day moving average of $31.01. Global Blood Therapeutics, Inc. has a twelve month low of $24.61 and a twelve month high of $43.98.

Global Blood Therapeutics (NASDAQ:GBTGet Rating) last announced its quarterly earnings results on Wednesday, February 23rd. The company reported ($1.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by ($0.22). Global Blood Therapeutics had a negative net margin of 155.63% and a negative return on equity of 102.42%. The firm had revenue of $56.10 million for the quarter, compared to the consensus estimate of $55.45 million. During the same period last year, the business earned ($1.00) EPS. Global Blood Therapeutics’s revenue was up 35.8% on a year-over-year basis. On average, sell-side analysts expect that Global Blood Therapeutics, Inc. will post -4.76 EPS for the current year.

GBT has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Global Blood Therapeutics in a research report on Friday, April 1st. Oppenheimer reduced their target price on Global Blood Therapeutics from $92.00 to $86.00 and set an “outperform” rating on the stock in a research note on Thursday, February 24th. Wedbush reissued an “outperform” rating on shares of Global Blood Therapeutics in a research note on Monday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Global Blood Therapeutics in a research note on Thursday, February 24th. Finally, Cowen reduced their price objective on Global Blood Therapeutics from $72.00 to $67.00 in a research note on Thursday, February 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, Global Blood Therapeutics presently has an average rating of “Buy” and an average price target of $62.79.

Global Blood Therapeutics Profile (Get Rating)

Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.

Further Reading

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.